ChemoINTEL Assay Algorithm Development Study

• Research type

  Research Study

• Full title

  ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients with Advanced Stage Epithelial Ovarian Cancer

• IRAS ID

  324870

• Contact name

  Rosie Lord

• Contact email

  rosemarylord@nhs.net

• Sponsor organisation

  Pierian Biosciences Limited

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial ovarian cancer (EOC) to develop a mathematical algorithm which will be able to predict a patient’s tumour’s sensitivity to specific chemotherapy drugs. The study involves using a sample of tumour biopsy taken during standard of care surgery, with a matched blood sample if possible. Medical history, pathology information and information on chemotherapy for up to 6 cycles will be requested. The information will then be used to developed an algorithm to predict tumour sensitivity to treatment.

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  23/NW/0216

• Date of REC Opinion

  31 Aug 2023

• REC opinion

  Further Information Favourable Opinion